Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
Purpose Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogen...
Saved in:
| Published in | The Journal of urology Vol. 192; no. 2; pp. 305 - 315 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
01.08.2014
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-5347 1527-3792 1527-3792 |
| DOI | 10.1016/j.juro.2014.02.2573 |
Cover
| Abstract | Purpose Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients. Materials and Methods The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients. Results Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist. Conclusions Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients. |
|---|---|
| AbstractList | Purpose Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients. Materials and Methods The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients. Results Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist. Conclusions Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients. Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients.PURPOSELow, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients.The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients.MATERIALS AND METHODSThe IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients.Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist.RESULTSCurrent definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist.Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients.CONCLUSIONSIntermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients. Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients. The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients. Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist. Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients. |
| Author | Persad, Raj Kamat, Ashish M Soloway, Mark Böhle, Andreas Witjes, J. Alfred Buckley, Roger Colombel, Marc Palou, Joan Lamm, Donald Brausi, Maurizio |
| Author_xml | – sequence: 1 fullname: Kamat, Ashish M – sequence: 2 fullname: Witjes, J. Alfred – sequence: 3 fullname: Brausi, Maurizio – sequence: 4 fullname: Soloway, Mark – sequence: 5 fullname: Lamm, Donald – sequence: 6 fullname: Persad, Raj – sequence: 7 fullname: Buckley, Roger – sequence: 8 fullname: Böhle, Andreas – sequence: 9 fullname: Colombel, Marc – sequence: 10 fullname: Palou, Joan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28613939$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24681333$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl-L1DAUxYOsuLOjn0CQvgi-tObmT5s-KKzjri4sCu764FNI01tNt5OOSTuw396UmUXYByUPIeR3Lpxz7hk58aNHQl4CLYBC-bYv-jmMBaMgCsoKJiv-hKxAsirnVc1OyIpSxnLJRXVKzmLsaSJlxZ6RUyZKBZzzFfnxETvnnf-ZGd9mtwHNtDymX5jd7NBOYd5mY5dd-QnDFltnJsy-uXiXfRn9do52wPS3N9HtMfswmLbFkG2Mtxiek6edGSK-ON5r8v3y4nbzOb_--ulqc36d25LJKa-AVQi0bqFplIK2azgKaS3DmqpWqRI7yrhEACyFULaRFGslBDAGqukEX5M3h7m7MP6eMU5666LFYTAexzlqkLKiCiTIhL46onOTzOhdcFsT7vVDHAl4fQRMtGboQnLi4l9OlcDrdNakPnA2jDEG7LR1U0pu9FMwbtBA9VKR7vVSkV4q0pTppaKk5Y-0D-P_rXp3UGGKcu8w6GgdppxbF1JNuh3df_TvH-ntkHpPJu_wHmM_zsGnljToyDTVN8vqLJsDgnIqoOZ_AKfovh0 |
| CODEN | JOURAA |
| CitedBy_id | crossref_primary_10_1093_milmed_usz166 crossref_primary_10_1007_s40846_015_0060_5 crossref_primary_10_1016_j_urolonc_2018_01_017 crossref_primary_10_1016_j_urolonc_2023_06_017 crossref_primary_10_1111_iju_15162 crossref_primary_10_3233_BLC_200311 crossref_primary_10_3233_BLC_160053 crossref_primary_10_1016_j_eururo_2015_06_023 crossref_primary_10_1016_j_euf_2018_11_005 crossref_primary_10_1111_bju_15254 crossref_primary_10_1097_MOU_0000000000000551 crossref_primary_10_1155_2021_5510318 crossref_primary_10_1016_j_urology_2016_01_004 crossref_primary_10_1016_j_urolonc_2016_05_028 crossref_primary_10_1586_14737140_2015_1115350 crossref_primary_10_1155_2020_5848493 crossref_primary_10_1097_CCO_0000000000000173 crossref_primary_10_1016_j_urolonc_2016_11_014 crossref_primary_10_1007_s00261_024_04737_3 crossref_primary_10_1097_MOU_0000000000000550 crossref_primary_10_1016_j_euf_2018_08_010 crossref_primary_10_1016_j_juro_2016_10_061 crossref_primary_10_1016_j_urolonc_2024_06_026 crossref_primary_10_1136_jitc_2021_002552 crossref_primary_10_1096_fj_201902626R crossref_primary_10_1016_j_juro_2016_01_087 crossref_primary_10_3389_fonc_2021_795242 crossref_primary_10_1038_nrurol_2017_16 crossref_primary_10_1073_pnas_1610472113 crossref_primary_10_1186_s40425_017_0271_0 crossref_primary_10_1016_j_euf_2020_05_004 crossref_primary_10_1111_iju_15309 crossref_primary_10_7759_cureus_17446 crossref_primary_10_1007_s00345_024_05417_z crossref_primary_10_33590_emjurol_10310878 crossref_primary_10_1038_s41598_017_01532_7 crossref_primary_10_1200_JCO_22_02104 crossref_primary_10_1007_s00345_018_2591_1 crossref_primary_10_1007_s00345_024_04992_5 crossref_primary_10_1016_j_euo_2019_06_003 crossref_primary_10_12688_f1000research_14903_1 crossref_primary_10_1097_CCO_0000000000000278 crossref_primary_10_1007_s11934_019_0952_y crossref_primary_10_1016_j_eururo_2021_12_005 crossref_primary_10_1097_MOU_0000000000001028 crossref_primary_10_48083_NJCD1236 crossref_primary_10_3389_fonc_2018_00642 crossref_primary_10_1016_j_euo_2022_05_005 crossref_primary_10_1016_j_euros_2021_01_015 crossref_primary_10_1111_bju_15209 crossref_primary_10_1038_nrurol_2014_172 crossref_primary_10_3892_mco_2018_1602 crossref_primary_10_1016_S0140_6736_22_01188_6 crossref_primary_10_1111_bju_14995 crossref_primary_10_1007_s00345_015_1595_3 crossref_primary_10_1038_nrurol_2015_58 crossref_primary_10_1155_2019_6702964 crossref_primary_10_1016_j_euo_2022_10_008 crossref_primary_10_1016_S0140_6736_16_30512_8 crossref_primary_10_1016_j_urology_2017_03_034 crossref_primary_10_1016_j_euf_2020_01_006 crossref_primary_10_1111_bju_16371 crossref_primary_10_1016_j_euo_2024_06_004 crossref_primary_10_1016_j_euo_2024_06_005 crossref_primary_10_1038_s41379_021_00955_y crossref_primary_10_1007_s00345_021_03740_3 crossref_primary_10_1016_j_urolonc_2016_05_033 crossref_primary_10_1016_j_urology_2022_12_009 crossref_primary_10_1200_JCO_2015_64_4070 |
| Cites_doi | 10.1016/j.eururo.2012.08.061 10.1016/j.eursup.2010.08.005 10.1016/j.eururo.2012.09.057 10.1111/j.1464-410X.2011.10571.x 10.1016/S0022-5347(05)67975-X 10.1016/S0302-2838(02)00068-4 10.1016/j.eururo.2009.12.024 10.1016/j.eururo.2009.11.041 10.1111/j.1464-410X.2012.11500.x 10.1016/j.urology.2005.07.063 10.1016/j.eursup.2011.03.002 10.1016/j.eururo.2009.01.006 10.1016/j.eururo.2009.05.047 10.1016/S0022-5347(05)64043-8 10.1016/S0022-5347(17)38731-1 10.1016/S0022-5347(17)51695-X 10.1016/S0022-5347(17)45923-4 10.1016/j.juro.2008.03.038 10.1016/j.eururo.2007.12.033 10.3109/01913123.2012.681833 10.1016/j.eururo.2005.12.031 10.1046/j.1464-410X.2003.04360.x 10.1016/j.juro.2011.07.076 10.1016/j.eururo.2007.04.062 10.1016/j.eururo.2009.04.038 10.1080/00365590310008037 10.1159/000019859 10.1016/j.eururo.2013.03.059 10.1016/j.juro.2007.09.003 10.1016/j.eururo.2007.10.006 10.1016/S0022-5347(01)61607-0 10.1016/j.eururo.2009.04.009 10.1016/S1569-9056(09)60669-2 10.1016/0959-8049(95)00287-S 10.1016/j.eururo.2009.03.052 10.1016/j.eururo.2012.10.039 10.1111/j.1464-410X.2010.09891.x 10.1016/j.eururo.2011.05.033 10.1016/S0022-5347(05)67280-1 10.1111/j.1464-410X.2009.08654.x 10.1016/j.eururo.2007.12.026 10.1016/j.eururo.2013.07.021 10.1016/j.eursup.2010.02.002 10.1111/bju.12012 10.1016/j.eururo.2013.06.003 |
| ContentType | Journal Article |
| Copyright | American Urological Association Education and Research, Inc. 2014 American Urological Association Education and Research, Inc. 2015 INIST-CNRS Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: American Urological Association Education and Research, Inc. – notice: 2014 American Urological Association Education and Research, Inc. – notice: 2015 INIST-CNRS – notice: Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.juro.2014.02.2573 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| EndPage | 315 |
| ExternalDocumentID | 24681333 28613939 10_1016_j_juro_2014_02_2573 S0022534714030419 1_s2_0_S0022534714030419 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016672 |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABVCZ ABWVN ACGFS ACIJW ACILI ACLDA ACOAL ACRPL ACXJB ADGGA ADHPY ADMUD ADNKB ADNMO ADPAM ADZCM AEBDS AEETU AENEX AFDTB AFEXH AFFNX AFTRI AFUWQ AGHFR AHOMT AHQNM AHRYX AHVBC AI. AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CS3 DIWNM DU5 EBS EEVPB EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P PKN QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN AGZHU AHPSJ ALXNB ZA5 AAYXX ABPXF ABXYN ABZZY ACVFH ACZKN ADCNI ADGHP AFBFQ AFNMH AGQPQ AHQVU AIGII AOQMC CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c625t-7127e109d1bb881dfb3e45cc2e908d886ef0235e11e6448cb50e984412218bf43 |
| ISSN | 0022-5347 1527-3792 |
| IngestDate | Fri Sep 05 09:23:24 EDT 2025 Thu Apr 03 07:03:34 EDT 2025 Wed Apr 02 07:18:32 EDT 2025 Tue Jul 01 04:30:09 EDT 2025 Thu Apr 24 23:06:09 EDT 2025 Fri Feb 23 02:30:55 EST 2024 Sun Feb 23 10:19:42 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | carcinoma in situ mitomycin C bacillus Calmette-Guérin NCCN NMIBC TURBT administration ICUD nonmuscle invasive bladder cancer chemotherapy AUA Southwest Oncology Group European Organisation for Research and Treatment of Cancer International Consultation on Urological Diseases PDD International Bladder Cancer Group narrow band imaging transurethral resection of bladder tumor NBI adjuvant urinary bladder neoplasms American Urological Association CUETO SWOG photodynamic diagnosis IBCG MMC intermediate risk EORTC BCG IR CIS European Association of Urology Club Urologico Espanol de Tratamiento Oncologico mycobacterium bovis EAU intravesical risk National Comprehensive Cancer Network Nephrology chemotherapy, adjuvant Urology Urinary bladder Bacteria Invasive cancer Urinary system disease Mycobacterium bovis Urinary tract disease Malignant tumor Bladder cancer Bladder tumor Chemotherapy Treatment Urinary system Mycobacteriales Risk factor Mycobacteriaceae Actinomycetes Bladder disease Intravesical administration Cancer |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c625t-7127e109d1bb881dfb3e45cc2e908d886ef0235e11e6448cb50e984412218bf43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/4687397 |
| PMID | 24681333 |
| PQID | 1557081515 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1557081515 pubmed_primary_24681333 pascalfrancis_primary_28613939 crossref_citationtrail_10_1016_j_juro_2014_02_2573 crossref_primary_10_1016_j_juro_2014_02_2573 elsevier_sciencedirect_doi_10_1016_j_juro_2014_02_2573 elsevier_clinicalkeyesjournals_1_s2_0_S0022534714030419 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-08-01 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2014 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Millán-Rodríguez, Chéchile-Toniolo, Salvador-Bayarri (bib46) 2000; 164 Brausi (bib2) 2010; 9 Oddens, Brausi, Sylvester (bib19) 2013; 63 Heney, Ahmed, Flanagan (bib37) 1983; 130 Babjuk, Burger, Zigeuner (bib6) 2013; 64 Brausi, Collette, Kurth (bib23) 2002; 41 May, Brookman-Amissah, Roigas (bib31) 2010; 57 Dobruch, Herr (bib12) 2009; 104 Hendricksen, Witjes, Idema (bib20) 2008; 53 Brausi, Oddens, Sylvester (bib50) 2014; 65 Sos, Palou, Huguet (bib27) 2009; 8 Burger, van der Aa, van Oers (bib32) 2008; 54 Kurth, Denis, Bouffioux (bib43) 1995; 31A Thalmann, Birkhäuser, Roth (bib35) 2011; 10 Böhle, Jocham, Bock (bib14) 2003; 169 Oosterlinck, Solsona, Akaza (bib45) 2005; 66 Sylvester, van der Meijden, Oosterlinck (bib33) 2006; 49 (bib10) 2014 Larsson, Wijkström, Thorstenson (bib40) 2003; 37 Millán-Rodríguez, Chéchile-Toniolo, Salvador-Bayarri (bib38) 2000; 163 Kamat, Hegarty, Gee (bib22) 2013; 63 Gudjónsson, Adell, Merdasa (bib11) 2009; 55 Parmar, Freedman, Hargreave (bib36) 1989; 142 Hinotsu, Akaza, Naito (bib16) 2011; 108 van der Meijden, Oosterlinck, Brausi (bib26) 1999; 35 Ojea, Nogueira, Solsona (bib15) 2007; 52 Hall, Chang, Dalbagni (bib8) 2007; 178 Fernandez-Gomez, Madero, Solsona (bib34) 2011; 60 Lamm, Persad, Colombel (bib1) 2010; 9 Zheng, Lv, Zhong (bib30) 2012; 110 Burger, Grossman, Droller (bib28) 2013; 64 Malmström, Wijkström, Lundholm (bib47) 1999; 161 Babjuk, Burger, Zigeuner (bib5) 2013 Sylvester, Brausi, Kirkels (bib18) 2010; 57 Konety, Oosterlinck, Chang (bib4) 2012 Cai, Nesi, Tinacci (bib13) 2008; 180 Hall, Chang, Dalbagni (bib7) 2007 Jӓrvinen, Kaasinen, Sankila (bib21) 2009; 56 Ali-El-Dein, Sarhan, Hinev (bib42) 2003; 92 Malmström, Sylvester, Crawford (bib17) 2009; 56 Kausch, Sommerauer, Montorsi (bib29) 2010; 57 Fitzpatrick, West, Butler (bib41) 1986; 135 Mariappan, Zachou, Grigor (bib24) 2010; 57 Ajili, Manai, Darouiche (bib39) 2012; 36 Witjes, Palou, Soloway (bib3) 2013; 112 Brausi, Witjes, Lamm (bib9) 2011; 186 Mariappan, Finney, Head (bib25) 2012; 109 Fernandez-Gomez, Solsona, Unda (bib44) 2008; 53 Mangiarotti, Trinchieri, Del Nero, Montanari (bib48) 2008; 80 Burger, Oosterlinck, Konety (bib49) 2013; 63 Fernandez-Gomez (10.1016/j.juro.2014.02.2573_bib34) 2011; 60 Witjes (10.1016/j.juro.2014.02.2573_bib3) 2013; 112 van der Meijden (10.1016/j.juro.2014.02.2573_bib26) 1999; 35 Zheng (10.1016/j.juro.2014.02.2573_bib30) 2012; 110 Malmström (10.1016/j.juro.2014.02.2573_bib17) 2009; 56 Fitzpatrick (10.1016/j.juro.2014.02.2573_bib41) 1986; 135 Ojea (10.1016/j.juro.2014.02.2573_bib15) 2007; 52 Larsson (10.1016/j.juro.2014.02.2573_bib40) 2003; 37 Babjuk (10.1016/j.juro.2014.02.2573_bib5) 2013 Mariappan (10.1016/j.juro.2014.02.2573_bib24) 2010; 57 Malmström (10.1016/j.juro.2014.02.2573_bib47) 1999; 161 Cai (10.1016/j.juro.2014.02.2573_bib13) 2008; 180 Burger (10.1016/j.juro.2014.02.2573_bib49) 2013; 63 Thalmann (10.1016/j.juro.2014.02.2573_bib35) 2011; 10 Burger (10.1016/j.juro.2014.02.2573_bib32) 2008; 54 Mariappan (10.1016/j.juro.2014.02.2573_bib25) 2012; 109 Kurth (10.1016/j.juro.2014.02.2573_bib43) 1995; 31A Brausi (10.1016/j.juro.2014.02.2573_bib23) 2002; 41 Mangiarotti (10.1016/j.juro.2014.02.2573_bib48) 2008; 80 Gudjónsson (10.1016/j.juro.2014.02.2573_bib11) 2009; 55 Hinotsu (10.1016/j.juro.2014.02.2573_bib16) 2011; 108 Jӓrvinen (10.1016/j.juro.2014.02.2573_bib21) 2009; 56 Böhle (10.1016/j.juro.2014.02.2573_bib14) 2003; 169 Oosterlinck (10.1016/j.juro.2014.02.2573_bib45) 2005; 66 Hall (10.1016/j.juro.2014.02.2573_bib7) 2007 Millán-Rodríguez (10.1016/j.juro.2014.02.2573_bib38) 2000; 163 Sylvester (10.1016/j.juro.2014.02.2573_bib18) 2010; 57 Oddens (10.1016/j.juro.2014.02.2573_bib19) 2013; 63 Konety (10.1016/j.juro.2014.02.2573_bib4) 2012 Burger (10.1016/j.juro.2014.02.2573_bib28) 2013; 64 Parmar (10.1016/j.juro.2014.02.2573_bib36) 1989; 142 Babjuk (10.1016/j.juro.2014.02.2573_bib6) 2013; 64 Fernandez-Gomez (10.1016/j.juro.2014.02.2573_bib44) 2008; 53 Hendricksen (10.1016/j.juro.2014.02.2573_bib20) 2008; 53 Millán-Rodríguez (10.1016/j.juro.2014.02.2573_bib46) 2000; 164 Ali-El-Dein (10.1016/j.juro.2014.02.2573_bib42) 2003; 92 Dobruch (10.1016/j.juro.2014.02.2573_bib12) 2009; 104 May (10.1016/j.juro.2014.02.2573_bib31) 2010; 57 Hall (10.1016/j.juro.2014.02.2573_bib8) 2007; 178 Lamm (10.1016/j.juro.2014.02.2573_bib1) 2010; 9 Kamat (10.1016/j.juro.2014.02.2573_bib22) 2013; 63 Kausch (10.1016/j.juro.2014.02.2573_bib29) 2010; 57 Heney (10.1016/j.juro.2014.02.2573_bib37) 1983; 130 Brausi (10.1016/j.juro.2014.02.2573_bib2) 2010; 9 Sos (10.1016/j.juro.2014.02.2573_bib27) 2009; 8 Brausi (10.1016/j.juro.2014.02.2573_bib9) 2011; 186 Brausi (10.1016/j.juro.2014.02.2573_bib50) 2014; 65 Ajili (10.1016/j.juro.2014.02.2573_bib39) 2012; 36 (10.1016/j.juro.2014.02.2573_bib10) 2014 Sylvester (10.1016/j.juro.2014.02.2573_bib33) 2006; 49 19346063 - Eur Urol. 2010 May;57(5):850-8 10419345 - Eur Urol. 1999 Apr;35(4):267-71 10081852 - J Urol. 1999 Apr;161(4):1124-7 16399417 - Urology. 2005 Dec;66(6 Suppl 1):75-89 21621906 - Eur Urol. 2011 Sep;60(3):423-30 19235434 - Arch Ital Urol Androl. 2008 Dec;80(4):167-71 23141049 - Eur Urol. 2013 Mar;63(3):462-72 17485161 - Eur Urol. 2007 Nov;52(5):1398-406 8541110 - Eur J Cancer. 1995 Oct;31A(11):1840-6 20034729 - Eur Urol. 2010 May;57(5):766-73 19395154 - Eur Urol. 2009 Aug;56(2):260-5 12775276 - Scand J Urol Nephrol. 2003;37(3):195-201 12930428 - BJU Int. 2003 Sep;92(4):393-9 18248876 - Eur Urol. 2008 May;53(5):984-91 3959241 - J Urol. 1986 May;135(5):920-2 23827737 - Eur Urol. 2013 Oct;64(4):639-53 17993339 - J Urol. 2007 Dec;178(6):2314-30 22981672 - Eur Urol. 2013 Jan;63(1):36-44 2501516 - J Urol. 1989 Aug;142(2 Pt 1):284-8 22985502 - BJU Int. 2012 Dec;110(11 Pt B):E680-7 19409692 - Eur Urol. 2009 Aug;56(2):247-56 23910233 - Eur Urol. 2014 Jan;65(1):69-76 20004052 - Eur Urol. 2010 Apr;57(4):595-606 19153001 - Eur Urol. 2009 Apr;55(4):773-80 10954628 - J Urol. 2000 Sep;164(3 Pt 1):680-4 6644886 - J Urol. 1983 Dec;130(6):1083-6 19524354 - Eur Urol. 2010 May;57(5):843-9 17950987 - Eur Urol. 2008 May;53(5):992-1001 18166262 - Eur Urol. 2008 Oct;54(4):835-43 10604317 - J Urol. 2000 Jan;163(1):73-8 23083902 - Eur Urol. 2013 Jan;63(1):4-15 23025650 - Ultrastruct Pathol. 2012 Oct;36(5):320-4 23602406 - Eur Urol. 2013 Nov;64(5):846-54 23452187 - BJU Int. 2013 Oct;112(6):742-50 16442208 - Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7 22014799 - J Urol. 2011 Dec;186(6):2158-67 22044434 - BJU Int. 2012 Jun;109(11):1666-73 12478111 - J Urol. 2003 Jan;169(1):90-5 18485394 - J Urol. 2008 Jul;180(1):110-5 12074794 - Eur Urol. 2002 May;41(5):523-31 19493266 - BJU Int. 2009 Jul;104(2):170-4 21176079 - BJU Int. 2011 Jul;108(2):187-95 |
| References_xml | – volume: 9 start-page: 406 year: 2010 ident: bib2 article-title: Challenging the EAU guidelines on non-muscle-invasive bladder cancer (NMIBC): single instillation of chemotherapy after transurethral resection of NMIBC and chemotherapy versus bacillus Calmette-Guérin in treatment of intermediate-risk tumours publication-title: Eur Urol Suppl – year: 2014 ident: bib10 article-title: Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1 – volume: 110 start-page: E680 year: 2012 ident: bib30 article-title: Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis publication-title: BJU Int – volume: 104 start-page: 170 year: 2009 ident: bib12 article-title: Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? publication-title: BJU Int – volume: 163 start-page: 73 year: 2000 ident: bib38 article-title: Multivariate analysis of the prognostic factors of primary superficial bladder cancer publication-title: J Urol – volume: 56 start-page: 260 year: 2009 ident: bib21 article-title: Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up publication-title: Eur Urol – volume: 57 start-page: 766 year: 2010 ident: bib18 article-title: Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder publication-title: Eur Urol – volume: 108 start-page: 187 year: 2011 ident: bib16 article-title: Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive cancer publication-title: BJU Int – volume: 164 start-page: 680 year: 2000 ident: bib46 article-title: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence publication-title: J Urol – volume: 63 start-page: 462 year: 2013 ident: bib19 article-title: Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance publication-title: Eur Urol – start-page: 231 year: 2012 end-page: 246 ident: bib4 article-title: Low-grade Ta urothelial carcinoma of the bladder publication-title: Bladder Cancer, 2nd ed – volume: 60 start-page: 423 year: 2011 ident: bib34 article-title: The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables publication-title: Eur Urol – volume: 57 start-page: 843 year: 2010 ident: bib24 article-title: Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience publication-title: Eur Urol – volume: 112 start-page: 742 year: 2013 ident: bib3 article-title: Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS) publication-title: BJU Int – volume: 8 start-page: 289 year: 2009 ident: bib27 article-title: Comparison of WHO 1973 to WHO 2004 grading system in bladder cancer related to association to CIS, recurrence and progression in Ta tumours publication-title: Eur Urol Suppl – volume: 135 start-page: 920 year: 1986 ident: bib41 article-title: Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection publication-title: J Urol – volume: 52 start-page: 1398 year: 2007 ident: bib15 article-title: A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C publication-title: Eur Urol – volume: 53 start-page: 984 year: 2008 ident: bib20 article-title: Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer publication-title: Eur Urol – volume: 109 start-page: 1666 year: 2012 ident: bib25 article-title: Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking publication-title: BJU Int – volume: 57 start-page: 850 year: 2010 ident: bib31 article-title: Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications publication-title: Eur Urol – volume: 35 start-page: 267 year: 1999 ident: bib26 article-title: Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee publication-title: Eur Urol – volume: 56 start-page: 247 year: 2009 ident: bib17 article-title: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer publication-title: Eur Urol – year: 2013 ident: bib5 article-title: Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS) – volume: 186 start-page: 2158 year: 2011 ident: bib9 article-title: A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group publication-title: J Urol – volume: 53 start-page: 992 year: 2008 ident: bib44 article-title: Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials publication-title: Eur Urol – volume: 63 start-page: 4 year: 2013 ident: bib22 article-title: ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers publication-title: Eur Urol – volume: 180 start-page: 110 year: 2008 ident: bib13 article-title: Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study publication-title: J Urol – volume: 36 start-page: 320 year: 2012 ident: bib39 article-title: Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy publication-title: Ultrastruct Pathol – volume: 55 start-page: 773 year: 2009 ident: bib11 article-title: Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study publication-title: Eur Urol – volume: 9 start-page: 715 year: 2010 ident: bib1 article-title: Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer publication-title: Eur Urol Suppl – volume: 130 start-page: 1083 year: 1983 ident: bib37 article-title: Superficial bladder cancer: progression and recurrence publication-title: J Urol – volume: 80 start-page: 167 year: 2008 ident: bib48 article-title: A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy publication-title: Arch Ital Urol Androl – volume: 66 start-page: 75 year: 2005 ident: bib45 article-title: Low-grade Ta (noninvasive) urothelial carcinoma of the bladder publication-title: Urology – volume: 178 start-page: 2314 year: 2007 ident: bib8 article-title: Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update publication-title: J Urol – volume: 65 start-page: 69 year: 2014 ident: bib50 article-title: Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG publication-title: Eur Urol – volume: 64 start-page: 639 year: 2013 ident: bib6 article-title: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 publication-title: Eur Urol – volume: 92 start-page: 393 year: 2003 ident: bib42 article-title: Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index publication-title: BJU Int – volume: 63 start-page: 36 year: 2013 ident: bib49 article-title: ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder publication-title: Eur Urol – volume: 41 start-page: 523 year: 2002 ident: bib23 article-title: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies publication-title: Eur Urol – volume: 10 start-page: e1 year: 2011 ident: bib35 article-title: Management of pT1G3 bladder cancer publication-title: Eur Urol Suppl – volume: 49 start-page: 466 year: 2006 ident: bib33 article-title: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials publication-title: Eur Urol – year: 2007 ident: bib7 article-title: Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update – volume: 31A start-page: 1840 year: 1995 ident: bib43 article-title: Factors affecting recurrence and progression in superficial bladder tumours publication-title: Eur J Cancer – volume: 57 start-page: 595 year: 2010 ident: bib29 article-title: Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies publication-title: Eur Urol – volume: 142 start-page: 284 year: 1989 ident: bib36 article-title: Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) publication-title: J Urol – volume: 169 start-page: 90 year: 2003 ident: bib14 article-title: Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity publication-title: J Urol – volume: 37 start-page: 195 year: 2003 ident: bib40 article-title: A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years publication-title: Scand J Urol Nephrol – volume: 64 start-page: 846 year: 2013 ident: bib28 article-title: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data publication-title: Eur Urol – volume: 54 start-page: 835 year: 2008 ident: bib32 article-title: Prediction of progression of non muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study publication-title: Eur Urol – volume: 161 start-page: 1124 year: 1999 ident: bib47 article-title: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group publication-title: J Urol – volume: 63 start-page: 36 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib49 article-title: ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder publication-title: Eur Urol doi: 10.1016/j.eururo.2012.08.061 – volume: 9 start-page: 715 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib1 article-title: Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer publication-title: Eur Urol Suppl doi: 10.1016/j.eursup.2010.08.005 – volume: 63 start-page: 4 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib22 article-title: ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers publication-title: Eur Urol doi: 10.1016/j.eururo.2012.09.057 – volume: 109 start-page: 1666 year: 2012 ident: 10.1016/j.juro.2014.02.2573_bib25 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10571.x – volume: 163 start-page: 73 year: 2000 ident: 10.1016/j.juro.2014.02.2573_bib38 article-title: Multivariate analysis of the prognostic factors of primary superficial bladder cancer publication-title: J Urol doi: 10.1016/S0022-5347(05)67975-X – volume: 41 start-page: 523 year: 2002 ident: 10.1016/j.juro.2014.02.2573_bib23 article-title: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies publication-title: Eur Urol doi: 10.1016/S0302-2838(02)00068-4 – volume: 57 start-page: 766 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib18 publication-title: Eur Urol doi: 10.1016/j.eururo.2009.12.024 – volume: 57 start-page: 595 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib29 article-title: Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies publication-title: Eur Urol doi: 10.1016/j.eururo.2009.11.041 – volume: 110 start-page: E680 year: 2012 ident: 10.1016/j.juro.2014.02.2573_bib30 article-title: Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis publication-title: BJU Int doi: 10.1111/j.1464-410X.2012.11500.x – volume: 66 start-page: 75 year: 2005 ident: 10.1016/j.juro.2014.02.2573_bib45 article-title: Low-grade Ta (noninvasive) urothelial carcinoma of the bladder publication-title: Urology doi: 10.1016/j.urology.2005.07.063 – volume: 10 start-page: e1 year: 2011 ident: 10.1016/j.juro.2014.02.2573_bib35 article-title: Management of pT1G3 bladder cancer publication-title: Eur Urol Suppl doi: 10.1016/j.eursup.2011.03.002 – volume: 55 start-page: 773 year: 2009 ident: 10.1016/j.juro.2014.02.2573_bib11 article-title: Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study publication-title: Eur Urol doi: 10.1016/j.eururo.2009.01.006 – volume: 57 start-page: 843 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib24 article-title: Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience publication-title: Eur Urol doi: 10.1016/j.eururo.2009.05.047 – volume: 169 start-page: 90 year: 2003 ident: 10.1016/j.juro.2014.02.2573_bib14 article-title: Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity publication-title: J Urol doi: 10.1016/S0022-5347(05)64043-8 – volume: 142 start-page: 284 year: 1989 ident: 10.1016/j.juro.2014.02.2573_bib36 article-title: Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) publication-title: J Urol doi: 10.1016/S0022-5347(17)38731-1 – volume: 80 start-page: 167 year: 2008 ident: 10.1016/j.juro.2014.02.2573_bib48 article-title: A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy publication-title: Arch Ital Urol Androl – volume: 130 start-page: 1083 year: 1983 ident: 10.1016/j.juro.2014.02.2573_bib37 article-title: Superficial bladder cancer: progression and recurrence publication-title: J Urol doi: 10.1016/S0022-5347(17)51695-X – volume: 135 start-page: 920 year: 1986 ident: 10.1016/j.juro.2014.02.2573_bib41 article-title: Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection publication-title: J Urol doi: 10.1016/S0022-5347(17)45923-4 – year: 2014 ident: 10.1016/j.juro.2014.02.2573_bib10 – volume: 180 start-page: 110 year: 2008 ident: 10.1016/j.juro.2014.02.2573_bib13 article-title: Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study publication-title: J Urol doi: 10.1016/j.juro.2008.03.038 – start-page: 231 year: 2012 ident: 10.1016/j.juro.2014.02.2573_bib4 article-title: Low-grade Ta urothelial carcinoma of the bladder – volume: 53 start-page: 984 year: 2008 ident: 10.1016/j.juro.2014.02.2573_bib20 article-title: Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2007.12.033 – volume: 36 start-page: 320 year: 2012 ident: 10.1016/j.juro.2014.02.2573_bib39 article-title: Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy publication-title: Ultrastruct Pathol doi: 10.3109/01913123.2012.681833 – volume: 49 start-page: 466 year: 2006 ident: 10.1016/j.juro.2014.02.2573_bib33 article-title: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials publication-title: Eur Urol doi: 10.1016/j.eururo.2005.12.031 – volume: 92 start-page: 393 year: 2003 ident: 10.1016/j.juro.2014.02.2573_bib42 article-title: Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index publication-title: BJU Int doi: 10.1046/j.1464-410X.2003.04360.x – volume: 186 start-page: 2158 year: 2011 ident: 10.1016/j.juro.2014.02.2573_bib9 article-title: A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group publication-title: J Urol doi: 10.1016/j.juro.2011.07.076 – volume: 52 start-page: 1398 year: 2007 ident: 10.1016/j.juro.2014.02.2573_bib15 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.04.062 – volume: 56 start-page: 247 year: 2009 ident: 10.1016/j.juro.2014.02.2573_bib17 article-title: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2009.04.038 – volume: 37 start-page: 195 year: 2003 ident: 10.1016/j.juro.2014.02.2573_bib40 article-title: A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years publication-title: Scand J Urol Nephrol doi: 10.1080/00365590310008037 – volume: 35 start-page: 267 year: 1999 ident: 10.1016/j.juro.2014.02.2573_bib26 article-title: Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee publication-title: Eur Urol doi: 10.1159/000019859 – volume: 64 start-page: 846 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib28 article-title: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.059 – volume: 178 start-page: 2314 year: 2007 ident: 10.1016/j.juro.2014.02.2573_bib8 article-title: Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update publication-title: J Urol doi: 10.1016/j.juro.2007.09.003 – volume: 53 start-page: 992 year: 2008 ident: 10.1016/j.juro.2014.02.2573_bib44 article-title: Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials publication-title: Eur Urol doi: 10.1016/j.eururo.2007.10.006 – volume: 161 start-page: 1124 year: 1999 ident: 10.1016/j.juro.2014.02.2573_bib47 article-title: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group publication-title: J Urol doi: 10.1016/S0022-5347(01)61607-0 – volume: 56 start-page: 260 year: 2009 ident: 10.1016/j.juro.2014.02.2573_bib21 publication-title: Eur Urol doi: 10.1016/j.eururo.2009.04.009 – volume: 8 start-page: 289 year: 2009 ident: 10.1016/j.juro.2014.02.2573_bib27 article-title: Comparison of WHO 1973 to WHO 2004 grading system in bladder cancer related to association to CIS, recurrence and progression in Ta tumours publication-title: Eur Urol Suppl doi: 10.1016/S1569-9056(09)60669-2 – volume: 31A start-page: 1840 year: 1995 ident: 10.1016/j.juro.2014.02.2573_bib43 article-title: Factors affecting recurrence and progression in superficial bladder tumours publication-title: Eur J Cancer doi: 10.1016/0959-8049(95)00287-S – volume: 57 start-page: 850 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib31 article-title: Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications publication-title: Eur Urol doi: 10.1016/j.eururo.2009.03.052 – volume: 63 start-page: 462 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib19 article-title: Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance publication-title: Eur Urol doi: 10.1016/j.eururo.2012.10.039 – volume: 108 start-page: 187 year: 2011 ident: 10.1016/j.juro.2014.02.2573_bib16 article-title: Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive cancer publication-title: BJU Int doi: 10.1111/j.1464-410X.2010.09891.x – volume: 60 start-page: 423 year: 2011 ident: 10.1016/j.juro.2014.02.2573_bib34 article-title: The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables publication-title: Eur Urol doi: 10.1016/j.eururo.2011.05.033 – volume: 164 start-page: 680 year: 2000 ident: 10.1016/j.juro.2014.02.2573_bib46 article-title: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence publication-title: J Urol doi: 10.1016/S0022-5347(05)67280-1 – volume: 104 start-page: 170 year: 2009 ident: 10.1016/j.juro.2014.02.2573_bib12 article-title: Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08654.x – volume: 54 start-page: 835 year: 2008 ident: 10.1016/j.juro.2014.02.2573_bib32 article-title: Prediction of progression of non muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study publication-title: Eur Urol doi: 10.1016/j.eururo.2007.12.026 – year: 2007 ident: 10.1016/j.juro.2014.02.2573_bib7 – volume: 65 start-page: 69 year: 2014 ident: 10.1016/j.juro.2014.02.2573_bib50 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.07.021 – volume: 9 start-page: 406 year: 2010 ident: 10.1016/j.juro.2014.02.2573_bib2 article-title: Challenging the EAU guidelines on non-muscle-invasive bladder cancer (NMIBC): single instillation of chemotherapy after transurethral resection of NMIBC and chemotherapy versus bacillus Calmette-Guérin in treatment of intermediate-risk tumours publication-title: Eur Urol Suppl doi: 10.1016/j.eursup.2010.02.002 – volume: 112 start-page: 742 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib3 article-title: Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS) publication-title: BJU Int doi: 10.1111/bju.12012 – year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib5 – volume: 64 start-page: 639 year: 2013 ident: 10.1016/j.juro.2014.02.2573_bib6 article-title: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.06.003 – reference: 10604317 - J Urol. 2000 Jan;163(1):73-8 – reference: 20034729 - Eur Urol. 2010 May;57(5):766-73 – reference: 19493266 - BJU Int. 2009 Jul;104(2):170-4 – reference: 23602406 - Eur Urol. 2013 Nov;64(5):846-54 – reference: 23827737 - Eur Urol. 2013 Oct;64(4):639-53 – reference: 18166262 - Eur Urol. 2008 Oct;54(4):835-43 – reference: 19346063 - Eur Urol. 2010 May;57(5):850-8 – reference: 20004052 - Eur Urol. 2010 Apr;57(4):595-606 – reference: 19153001 - Eur Urol. 2009 Apr;55(4):773-80 – reference: 12074794 - Eur Urol. 2002 May;41(5):523-31 – reference: 21621906 - Eur Urol. 2011 Sep;60(3):423-30 – reference: 22044434 - BJU Int. 2012 Jun;109(11):1666-73 – reference: 23910233 - Eur Urol. 2014 Jan;65(1):69-76 – reference: 2501516 - J Urol. 1989 Aug;142(2 Pt 1):284-8 – reference: 22981672 - Eur Urol. 2013 Jan;63(1):36-44 – reference: 19524354 - Eur Urol. 2010 May;57(5):843-9 – reference: 16442208 - Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7 – reference: 12930428 - BJU Int. 2003 Sep;92(4):393-9 – reference: 17993339 - J Urol. 2007 Dec;178(6):2314-30 – reference: 21176079 - BJU Int. 2011 Jul;108(2):187-95 – reference: 23141049 - Eur Urol. 2013 Mar;63(3):462-72 – reference: 17950987 - Eur Urol. 2008 May;53(5):992-1001 – reference: 10081852 - J Urol. 1999 Apr;161(4):1124-7 – reference: 23025650 - Ultrastruct Pathol. 2012 Oct;36(5):320-4 – reference: 19235434 - Arch Ital Urol Androl. 2008 Dec;80(4):167-71 – reference: 12775276 - Scand J Urol Nephrol. 2003;37(3):195-201 – reference: 19395154 - Eur Urol. 2009 Aug;56(2):260-5 – reference: 16399417 - Urology. 2005 Dec;66(6 Suppl 1):75-89 – reference: 22985502 - BJU Int. 2012 Dec;110(11 Pt B):E680-7 – reference: 6644886 - J Urol. 1983 Dec;130(6):1083-6 – reference: 18485394 - J Urol. 2008 Jul;180(1):110-5 – reference: 23452187 - BJU Int. 2013 Oct;112(6):742-50 – reference: 18248876 - Eur Urol. 2008 May;53(5):984-91 – reference: 10419345 - Eur Urol. 1999 Apr;35(4):267-71 – reference: 12478111 - J Urol. 2003 Jan;169(1):90-5 – reference: 19409692 - Eur Urol. 2009 Aug;56(2):247-56 – reference: 17485161 - Eur Urol. 2007 Nov;52(5):1398-406 – reference: 8541110 - Eur J Cancer. 1995 Oct;31A(11):1840-6 – reference: 10954628 - J Urol. 2000 Sep;164(3 Pt 1):680-4 – reference: 3959241 - J Urol. 1986 May;135(5):920-2 – reference: 22014799 - J Urol. 2011 Dec;186(6):2158-67 – reference: 23083902 - Eur Urol. 2013 Jan;63(1):4-15 |
| SSID | ssj0014572 |
| Score | 2.4376516 |
| SecondaryResourceType | review_article |
| Snippet | Purpose Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1,... Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS).... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 305 |
| SubjectTerms | adjuvant administration Algorithms Biological and medical sciences chemotherapy Humans intravesical Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) mycobacterium bovis Nephrology. Urinary tract diseases Practice Guidelines as Topic risk Risk Assessment Tumors Tumors of the urinary system urinary bladder neoplasms Urinary Bladder Neoplasms - classification Urinary Bladder Neoplasms - therapy Urinary tract. Prostate gland Urology |
| Title | Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0022534714030419 https://dx.doi.org/10.1016/j.juro.2014.02.2573 https://www.ncbi.nlm.nih.gov/pubmed/24681333 https://www.proquest.com/docview/1557081515 |
| Volume | 192 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMwxu7LLkWDvWUOlmTH8mObdSvt2oeRju5JWLJMG9Kk-MJY_8b-8I4sy3HIUra-mGAsRdb5dPzp3ITQhySgmulEewzosRdkceJJqSIvzGikCKVRRkxy8snp-PAsODoPz3u9352opaqUI3Xz17ySu0gV7oFcTZbsf0i27RRuwG-QL1xBwnD9Jxl_0ll9vkPtAZjW9K9JfjLHypd5deUyRfI6Q6TUw28mlPx0ubiqCujMlNlI6gD2_blRQflwYlCQdynrKnmspq1VvmaIP06A8tYKprgwxZE6hpxyZlXQ0Wi4N8_ckaDWf18VlzZTqMovb2woWG3ngb5_Jr_WkogakwQJ2oC4bopAyGwpzVbNxrSDJ9pRmswPO99fZtM7N1S7tTLMRjN4TxOSF5haq6Bw2OpL5rz3B5Nj4hV05HvGF03NSExZQj9otPN6gW0iCip8sfHoPbRDIyBkfbTzZf_r973WORWEUVuE3jRwxazqsMGN4W0jPA-vkwKWYWbPT9m-wamJzvQxetSIGu9ZuD1BPb14iu6fNDEYz9APhzoMqMMOdRhQhx3q8DLDXdRhgzrcog471OEGddii7jk6-3wwnRx6zQEdnoJtc-lFhEaa-HFKpOSw8ckk00GoFNWxz1POxzoz5ZQ0IdqYAZQMfR1zIOAUiKXMAvYC9RfLhX6FsM7Gyk9jlQa-DFLJ44THnCrNiGJcy3SAqJtFoZrq9eYQlblwYYozYaZemKkXPhVm6gfoY9vo2hZvuf3xyIlHuLxk-JLqolnyhdgGlQEaty0b5moZqQD03v6Xu2swaIdJOfDsmEHP7x0uBCh-481LFnpZwVhM8Txu9iMD9NICZtU6GHPCGHt95zd6gx6sVvZb1Afw6HdAv0u52yyHPxcX1pk |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Defining+and+Treating+the+Spectrum+of+Intermediate+Risk+Nonmuscle+Invasive+Bladder+Cancer&rft.jtitle=The+Journal+of+urology&rft.au=Kamat%2C+Ashish+M&rft.au=Witjes%2C+J.+Alfred&rft.au=Brausi%2C+Maurizio&rft.au=Soloway%2C+Mark&rft.date=2014-08-01&rft.issn=0022-5347&rft.volume=192&rft.issue=2&rft.spage=305&rft.epage=315&rft_id=info:doi/10.1016%2Fj.juro.2014.02.2573&rft.externalDBID=ECK1-s2.0-S0022534714030419&rft.externalDocID=1_s2_0_S0022534714030419 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00225347%2FS0022534713X00230%2Fcov150h.gif |